First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study - Wikidata - wikimedia - TriplyDB

First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

http://www.wikidata.org/entity/Q24803202

about

Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours Comparison of absolute neutrophil to CD4 lymphocyte values as a marker of immunosuppression in cancer patients on cytotoxic chemotherapy Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier.Pegfilgrastim -- rational drug design for the management of chemotherapy-induced neutropenia.G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.Canadian supportive care recommendations for the management of neutropenia in patients with cancer.Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer.Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.Impact of neutropenia on delivering planned chemotherapy for solid tumours.MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm.

P2860

Q34858123-C8866CD9-EF5C-44F6-BFEC-CF5D5E1A97CA Q35780507-B42D45E9-8E6C-4C31-8372-00BC1B6081B5 Q35791695-CCD3158B-73AF-4B26-B54B-4979E850F713 Q36297208-CDECBC92-5E47-41E6-845D-FE8A083D8E97 Q36443085-59E698DE-6DA4-43CE-B9FA-774E47F21AD5 Q36485208-977789B2-D3B5-4084-958B-67ED8C38248D Q36610747-C27AEF9A-C4FD-4450-B260-C03A4A8309B3 Q36762853-AB56C23A-097C-4815-8B3D-13B8EEF484A9 Q39698919-A33CC705-1E6B-429C-BE24-2FD5C64FD079 Q40307046-3160656B-B39F-4D11-922F-4BDFB7C0B4C9 Q46601899-01661457-CC79-4C7A-B6F3-A228C7C9E89D Q46817819-7C485011-933F-4E13-9765-E693F25A5E8C Q47419424-91FCB91C-EB60-49B3-BFC0-350DB27F3C25 Q55413674-7397E54F-A3CC-44E2-96B8-73548CFB9706

P2860

First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study

http://www.wikidata.org/entity/Q24803202

description

2003 nî lūn-bûn

@nan

2003 թուականին հրատարակուած գիտական յօդուած

@hyw

2003 թվականին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

First-cycle absolute neutrophi ...... nt therapy: a validation study

@ast

First-cycle absolute neutrophi ...... nt therapy: a validation study

@en

First-cycle absolute neutrophi ...... nt therapy: a validation study

@nl

type

label

First-cycle absolute neutrophi ...... nt therapy: a validation study

@ast

First-cycle absolute neutrophi ...... nt therapy: a validation study

@en

First-cycle absolute neutrophi ...... nt therapy: a validation study

@nl

prefLabel

First-cycle absolute neutrophi ...... nt therapy: a validation study

@ast

First-cycle absolute neutrophi ...... nt therapy: a validation study

@en

First-cycle absolute neutrophi ...... nt therapy: a validation study

@nl

P1433

Q24803202-1B0F6D32-0F6B-4EAE-9CB1-5542F6657632

P1476

Q24803202-CB29BA2E-FEA5-4678-BCB6-0A79EDA19A09

P2093

Q24803202-4B7B26F2-8D7A-4896-B7B4-35215706F818

Q24803202-7077BD9E-2F58-4238-A950-E7BEE2FA040E

Q24803202-84CB1063-FAB6-404C-B24F-430D79A316B1

Q24803202-94721A68-4990-4298-A618-E0F7017365A7

Q24803202-B67140B9-66F7-4399-83A8-5C3C3579EFAE

P2860

Q24803202-049EC886-38D4-4B6E-B6BB-CCF116261DBC

Q24803202-317FC73D-7949-4FA4-8BD2-55C448F74AE1

Q24803202-8835F84F-B045-4BCF-98A1-C949AFDE6993

Q24803202-A466F26D-1567-4E3B-869B-C9E793909706

Q24803202-A6E591F2-A436-44F9-AEDD-97F1E5114B44

Q24803202-C5548C2A-E810-4E9D-BFB1-DAD8811CAEDC

Q24803202-C574D855-15BC-44C3-9A4A-E08CA0FA70E7

P2888

Q24803202-1E8D946A-5E52-4E0D-AB96-EEA1E353A693

P304

Q24803202-DE3EB1AA-4FEA-4C68-AA58-4C025C867F6E

P31

Q24803202-3082F2F9-679A-4C05-B19C-1F5BCFEE276A

P356

Q24803202-13C988FF-EE30-48B4-BC76-60FCDC1605BB

P407

Q24803202-98328DE9-55FF-4DA7-A6E2-F9C3AD7EC62B

P433

Q24803202-ACCE0A1B-9278-41D4-B865-886521994077

P478

Q24803202-721AB581-5446-4D3D-820C-8F2C995B7A3A

P577

Q24803202-F6BADC8E-1F0E-4FBC-9185-E893436D8CFA

P5875

Q24803202-E532C787-7767-4EF2-BCA4-E7F39D04F47E

P6179

Q24803202-0FA2A871-89FA-4370-B4CB-477D8D8E8BAF

P698

Q24803202-4069E27E-CD93-4D40-A167-ECF6E9F492AF

P921

Q24803202-937AD334-EFC7-4B72-A672-F8F73692E65B

P932

Q24803202-499F2655-B301-478E-A3E2-264AE82B9F52

P356

P1433

Breast Cancer Research

P1476

First-cycle absolute neutrophi ...... nt therapy: a validation study

@en

P2093

Debra Frye

http://www.w3.org/2001/XMLSchema#string

Edgardo Rivera

http://www.w3.org/2001/XMLSchema#string

Gabriel N Hortobagyi

http://www.w3.org/2001/XMLSchema#string

M Haim Erder

http://www.w3.org/2001/XMLSchema#string

Moshe Fridman

http://www.w3.org/2001/XMLSchema#string

P2860

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.

Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care.

Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors.

Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

P2888

P304

R114-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR618

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10607026

http://www.w3.org/2001/XMLSchema#string

P6179

1036508147

http://www.w3.org/2001/XMLSchema#string

P698

12927041

http://www.w3.org/2001/XMLSchema#string

P921

P932

314422

http://www.w3.org/2001/XMLSchema#string